| Objective To clarify whether soluble leukocyte differentiation antigen 14 subtype(Soluble CD14 subtype,s CD14-st)can early diagnose neonatal early-onset sepsis(EOS),and compare Presepsin with CRP,PCT,IL-6 and other infection indicators,to discuss whether s CD14-st is better than the common clinical infection index in the diagnosis of neonatal early-onset sepsis.Method Neonates admitted to the Maternal and Child Health Hospital Affiliated to Anhui Medical University from August 2020 to February 2022 were collected,including those with clinical manifestations of neonatal sepsis and risk factors for sepsis(25 cases diagnosed with EOS).Neonates admitted to hospital for non-infectious reasons and negative for infection indicators(such as hyperbilirubinemia,aspiration pneumonia,neonatal swallowing syndrome,high-risk infants,etc.)during the same time period were selected as the control group(25cases in total).Before receiving antibacterial treatment and after 3 days of antibacterial treatment,blood s CD14-st,C-reactive protein(CRP),procalcitonin(PCT),interleukin-6(IL-6)in the sepsis group and infection group were measured,respectively.In the control group,s CD14-st,CRP,PCT and IL-6 were also measured.The differences of blood indexes between the children in the sepsis group and the control group were analyzed and compared ROC to evaluate the diagnostic performance of each index.Result The serum s CD14-st level in the EOS group was higher than that in the control group(P<0.05);the serum s CD14-st level in the EOS group was significantly higher than that after the antibacterial treatment(P<0.05);Compared with other indicators,it has the best diagnostic performance.Conclusion s CD14-st is significantly elevated in children with EOS,which can be used as a feasible biomarker for the diagnosis of EOS.After antibacterial treatment,the level of s CD14-st decreases significantly,which can be used to judge the efficacy of antibacterial treatment.In the diagnosis of EOS,s CD14-st has higher diagnostic performance than CRP,PCT,IL-6. |